NIH Clinical Research Studies Listed By Institute of the Principal Investigator

National Institute of Allergy and Infectious Diseases (NIAID)

170 Protocols (137 Active Accrual of new subjects, 33 Follow-up of previously enrolled subjects)

Active Accrual, Protocols Recruiting New Patients 
* 17-I-0163:
Natural History of Intestinal Inflammation in Patients with Primary Immune Dysregulations

* 17-I-0122:
Centralized Sequencing Protocol

* 17-I-0110:
VRC 316: A Phase I Open-Label Clinical Trial To Evaluate Dose, Safety, Tolerability, And Immunogenicity Of An Influenza HA Ferritin Vaccine, Alone Or In Prime-Boost Regimens With An Influenza DNA Vaccine In Healthy Adults

* 17-I-0106:
Comprehensive Evaluation of the Impact of a Short-Term Analytical Treatment Interruption and Re-Initiation of Antiretroviral Therapy on Immunologic and Virologic Parameters in HIV-Infected Individuals

* 17-I-0101:
An Open-Label, Phase I/II Pilot Study to Assess the Safety and Tolerability of Vorinostat for the Treatment of Moderate-to-Severe Crohn s Disease

* 17-I-0096:
An Expanded Access Treatment Protocol for ZMappTM for Patients with Ebola Virus Disease (EVD) or Ebola Virus Exposure

* 17-I-0072:
Herpesviruses Reactivation In Hiv-Infected Women Initiating ART (HERA)

* 17-I-0068:
CD8 Reactivity to Microorganisms in Blood and Breast Milk

* 17-I-0067:
Sanaria PfSPZ Challenge with Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Dose Escalation Trial to Determine Safety and Development of Protective Efficacy after Exposure to Only Pre-erythrocytic Stages of Plasmodium falciparum

* 17-I-0065:
A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1

* 17-I-0059:
Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine

* 17-I-0058:
VRC 317: A Phase I Randomized, Open-Label Clinical Trial to Evaluate Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or with Alum Adjuvant, in Healthy Adults

* 17-I-0047:
Treatment of Conditions Expected to Benefit from JAK 1/2 Inhibition: CANDLE, CANDLE Related Conditions, SAVI, and Severe Juvenile Dermatomyositis

* 17-I-0033:
Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis Phase I/II

* 17-I-0016:
Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still s-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)

* 16-I-0165:
Open-Label Long Term Extension Study To Evaluate CDZ173 In Patients With APDS/PASLI (Activated Phosphoinositide 3-Kinase Delta Syndrome/P110 Delta-Activating Mutation Causing Senescent T Cells, Lymphadenopathy And Immunodeficiency)

* 16-I-0147:
VRC 607: A Phase 1, Single Dose Study of the Safety and Virologic Effect of a Human MonoclonalAntibody, VRC-HIVMAB080-00-AB (VRC01LS), with Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults.

* 16-I-0118:
An Exploratory, Open-Label Study of Vedolizumab (anti-alpha4beta7 antibody) in Subjects with HIV Infection Undergoing Analytical Treatment Interruption

* 16-I-0078:
Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME study)

* 16-I-0053:
A Multicenter Study of the Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSVdeltaG-ZEBOV GP) for Pre-Exposure Prophylaxis in Individuals at Potential Occupational Risk for Ebola Virus Exposure (PREPARE)

* 16-I-0039:
Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge

* 16-I-0032:
High Dose Peripheral Blood Stem Cell Transplantation with Post Transplant Cyclophosphamide for Patients with Chronic Granulomatous Disease

* 16-I-0022:
A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Teatment of Severe Influenza A

* 16-I-0020:
Mepolizumab Long-term Access Program for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy)

* 16-I-0008:
Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers

* 16-I-0002:
A Phase IIa Efficacy, Safety, Tolerability and Pharmacokinetic Study of Encochleated Amphotericin B (CAMB) in Patients with Mucocutaneous (Esophogeal, Oropharyngeal, Vulvovaginal) Candidiasis Who are Refractory or Intolerant to Standard Non-Intravenous T

* 15-I-0187:
Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance

* 15-I-0162:
Natural History and Genetics of Food Allergy and Related Conditions

* 15-I-0161:
A Double-blind, Placebo-controlled, Crossover Study of Magnesium Supplementation in Patients with XMEN Syndrome

* 15-I-0154:
Long-Term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge

* 15-I-0135:
An Open-Label, Non-Randomized, Within-Patient Dose-Finding Study Followed by a Randomized, Double-Blind Placebo Controlled Study with Extension to Assess the Safety and Efficacy of CDZ173 in Patients with APDS/PASLI (Activated Phosphoinositide 3-kinase D

* 15-I-0131:
Xenodiagnosis after Antibiotic Treatment for Lyme Disease - Phase II Study

* 15-I-0122:
Partnership for Research on Ebola Virus (PREVAIL) III: Ebola Natural History Study

* 15-I-0094:
A Phase 1a Open-Label Study to Assess the Safety and Pharmacokinetics of a Single ZMappTM Administration in Healthy Adult Volunteers

* 15-I-0089:
Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG)

* 15-I-0069:
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study in Healthy Volunteers to Evaluate the Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Human Challenge Model

* 15-I-0056:
Collection of Plasma from Subjects that Recovered From or Were Vaccinated To Emerging Infectious Diseases

* 15-I-0036:
Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative UO1 Grant

* 15-I-0008:
A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patient with Xlinked Chronic Granulomatous Disease (CGD)

* 14-I-0206:
Novel Genetic Disorders of the Immune System

* 14-I-0199:
Human Immunity Against Staphylococcus Aureus Skin Infection

* 14-I-0194:
Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products

* 14-I-0185:
A Phase III Double-Blind Randomized Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients with WHIM Syndrome.

* 14-I-0153:
An Open-Label Phase I/II Pilot Study to Assess the Safety/Tolerability and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated with Common Variable Immunodeficiency

* 14-I-0146:
The Pathogenesis and Genetics of Disseminated or Refractory Coccidiodomycosis

* 14-I-0124:
PET Imaging and Lymph Node Assessment of IRIS in Persons With AIDS

* 14-I-0091:
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995

* 14-I-0089:
A Retrospective and Cross-Sectional Analysis of Patients Treated for Severe Combined Immunodeficiency (SCID) Since January 1, 1968

* 14-I-0081:
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Benralizumab (MEDI-563) in Reducing Eosinophilia in Subjects with Hypereosinophilic Syndrome (HES)

* 14-I-0072:
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders

* 14-I-0039:
Elite Controller and ART-Treated HIV+ Statin Versus ASA Treatment Intervention Study

* 14-I-0020:
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

* 14-I-0011:
Phase I Study of Safety and Immunogenicity of Ad4-HIV Vaccine Vectors in Healthy Volunteers

* 14-I-0009:
Characterization and Management of Patients with HIV-1 Infection Who Experience Virologic Failure Despite Combination Antiretroviral Therapy

* 13-I-0181:
Microbiomic and Immunologic Profiling of Women with Antibiotic induced Vaginal Candidiasis

* 13-I-0157:
The Natural History of GATA2 Deficiency and Related Disorders

* 13-I-0117:
Radiofrequency Ablation (RFA) for the Treatment of Liver Abscesses in Patients with Chronic Granulomatous Disease

* 13-I-0082:
Rituximab (Anti-CD20) for the Treatment of Subjects With Anticytokine Autoantibody-Associated Diseases

* 12-I-0157:
Clinical Outcomes in Persons with HIV Acquired Early in Life (COPE)

* 12-I-0121:
Screening of Volunteers for Clinical Trials of Investigational and Licensed Vaccines, Antiviral Products, or Live Virus Challenge Studies

* 12-I-0026:
Assessment of Glucocorticoid Responsiveness and Mechanisms of Resistance in Hypereosinophilic Syndromes

* 11-I-0259:
Phase 1 Study of Safety and Immunogenicity of Ad4-H5-VTN in Ad4 Seronegative and Seropositive Volunteers

* 11-I-0187:
The Natural History, Immunologic Correlates and Genetic Defects in Patients with Mucocutaneous and Invasive Fungal Infections

* 11-I-0183:
Screening of Volunteers for Influenza Human Challenge and Vaccine Studies

* 11-I-0164:
VRC 500:Screening of Volunteers for Clinical Trials of Investigational Products and Licensed Products Evaluated for Research Purposes

* 11-I-0109:
Viral Infections in Healthy and Immunocompromised Hosts

* 11-I-0031:
A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults

* 11-I-0007:
Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age with X-Linked Severe Combined Immunodeficiency

* 10-I-0216:
Studies of Disorders with Increased Susceptibility to Fungal Infections

* 10-I-0197:
Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases

* 10-I-0195:
Training Protocol on the Natural History of Tuberculosis

* 10-I-0148:
Natural History of Atopic Dermatitis and Other Genetic/Congenital Diseases Associated with Allergic Inflammation

* 10-I-0109:
VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older

* 10-I-0095:
Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Healthy Volunteers

* 10-I-0029:
Non-Invasive Assessment of Atherosclerosis in Patients with CGD and Other Disorders of the Immune System

* 10-I-0014:
The Natural History of Severe Viral Infections and Characterization of Immune Defects

* 09-I-0232:
An International Observational Study to Characterize Adults Who Are Hospitalized with Complications of Influenza

* 09-I-0200:
A Phase I Study of Mozobil (TM) in the Treatment of Patients with WHIMS

* 09-I-0184:
Studies in the Pathogenesis of Systemic Capillary Leak Syndrome

* 09-I-0133:
Establishing Fibroblast-derived Cell Lines from Skin/Tissue Biopsies of Patients with Immunodeficiency or Immunodysregulation Disorders

* 09-I-0129:
A Randomized Double-Blinded, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

* 09-I-0126:
Pathogenesis of Physical Induced Urticarial Syndromes

* 09-I-0102:
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

* 09-I-0086:
Screening Protocol for Genetic Diseases of Allergic Inflammation

* 09-I-0049:
Normal Blood, Bone Marrow and Buccal Mucosa Protocol

* 09-I-0030:
Clinical and Immunologic Monitoring of Patients with Known or Suspected HIV Infection

* 09-I-0013:
Biomarkers of Inflammation, Coagulation, and Endothelial Function in HIV-Infected Adults

* 08-I-0221:
Analysis of HIV-1 Replication During Antiretroviral Therapy

* 08-I-0184:
Studies in the Pathogenesis of Idiopathic Anaphylaxis

* 07-I-0229:
Influenza in the Non-immunocompromised and Immunocompromised Host

* 07-I-0183:
The Collection of Research Samples and/or Data for Repository from Related or Unrelated Hematopoietic Stem Cell Transplantation Recipients for the National Marrow Donor Program

* 07-I-0075:
Allogeneic and Matched Unrelated Donor Stem Cell Transplantation for Congenital Immunodeficiencies or Patients with Autoinflammatory/Immunodysregulatory Conditions: Busulfan-Based Conditioning with Campath- 1H or h-ATG, Radiation, and Sirolimus

* 07-I-0033:
Screening Protocol for Detection and Characterization of Infections and Infection Susceptibility

* 06-I-0153:
A Pilot Study of Hepatic Fibrosis in HIV/AIDS Patients with Chronically Elevated Transaminases on Antiretroviral Therapy

* 06-I-0015:
Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death

* 05-I-0219:
Analysis of Erythema Migrans Lesions

* 05-I-0213:
Screening and Baseline Assessment of Patients with Abnormalities of Immune Function

* 04-I-0286:
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression

* 04-I-0266:
Collection of Peripheral Blood, Urine, Sputum, and Bone Marrow from Healthy Donors for Use in In Vitro Research

* 03-I-0263:
VRC 200: A Multicenter Specimen Collection Protocol to Obtain Human Biological Samples for Research Studies

Next 70 Protocols

Command Menu Bar

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

Clinical Center LogoNational Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 10/21/2017

Search The Studies Help Questions
Search The Studies Help Questions